The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (review).

No abstract is available for this paper.

• Publication year

  1995

• Venue

  International Journal of Oncology

• Publication date

  1995-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3892/IJO.6.6.1291PMID 21556672
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of drug resistance in ovarian cancer

  2010cited by this paper
• Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes

  2005cited by this paper
• Studies on the human metabolism of iproplatin

  2004cited by this paper
• Short-termcis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells

  2004cited by this paper
• Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II)

  2004cited by this paper
• Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial

  2004cited by this paper
• Intracellular metabolites of cisplatin in the rat kidney

  2004cited by this paper
• Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits

  2004cited by this paper
• Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses

  2004cited by this paper
• In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines

  2004cited by this paper
• Phase I study of oxaliplatin in patients with advanced cancer

  2004cited by this paper
• Induction of UV-damage recognition protein by cisplatin treatment.

  1995cited by this paper
• Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes

  1994cited by this paper
• Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.

  1994cited by this paper
• Synthesis, structural characterization, and antitumor properties of a novel class of large-ring platinum(II) chelate complexes incorporating the cis-1,4-diaminocyclohexane ligand in a unique locked boat conformation.

  1994cited by this paper
• Signaling and drug sensitivity

  1994cited by this paper
• Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.

  1994cited by this paper
• Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cells.

  1994cited by this paper
• Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.

  1994cited by this paper
• The RAD6 DNA repair pathway in Saccharomyces cerevisiae: What does it do, and how does it do it?

  1994cited by this paper
• Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

  1994cited by this paper
• NUCLEOTIDE EXCISION REPAIR

  1993cited by this paper
• Differential interaction of cisplatin with the HIV-1 long terminal repeat in a resistant ovarian carcinoma cell line

  1993cited by this paper
• New Cisplatin Analogues in Development

  1993cited by this paper
• Cellular accumulation of the anticancer agent cisplatin: a review.

  1993cited by this paper
• Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

  1993cited by this paper
• In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.

  1993cited by this paper
• Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate.

  1993cited by this paper
• In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin.

  1993cited by this paper
• Comparative nephrotoxicity of tetraplatin and cisplatin in rats.

  1993cited by this paper
• The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents.

  1993cited by this paper
• Evidence of differential cisplatin‐DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines

  1993cited by this paper
• Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.

  1993cited by this paper
• Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.

  1993cited by this paper
• Role of carrier ligand in platinum resistance of human carcinoma cell lines.

  1993cited by this paper
• Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.

  1993cited by this paper
• Purification of a HeLa cell nuclear protein that binds selectively to DNA irradiated with ultra-violet light.

  1993cited by this paper
• Cytotoxicity of platinum(IV) and platinum(II) complexes containing 1R,2R-cyclohexanediamine as a ligand.

  1993cited by this paper
• cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway.

  1992cited by this paper
• Activation of the gadd153 promoter by genotoxic agents: a rapid and specific response to DNA damage.

  1992cited by this paper
• Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.

  1992cited by this paper
• Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines

  1992cited by this paper
• Monofunctional DNA-platinum(II) adducts block frequently DNA polymerases.

  1992cited by this paper
• The current status of new platinum analogs.

  1992cited by this paper
• Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes.

  1992cited by this paper
• Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts.

  1992cited by this paper
• Cisplatin-induced imbalances in the pattern of chimeric marker gene expression in HeLa cells.

  1992cited by this paper
• Purification of nuclear proteins that bind to cisplatin-damaged DNA. Identity with high mobility group proteins 1 and 2.

  1992cited by this paper
• Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin.

  1992cited by this paper
• A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

  1992cited by this paper
• Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.

  1992cited by this paper
• The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

  1991cited by this paper
• Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.

  1991cited by this paper
• Role of the Na+, K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells.

  1991cited by this paper
• Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum (II).

  1991cited by this paper
• Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.

  1991cited by this paper
• The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation.

  1991cited by this paper
• Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.

  1991cited by this paper
• An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.

  1991cited by this paper
• Cisplatin resistance in human cancers.

  1991cited by this paper
• Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines

  1991cited by this paper
• Cross-resistance to UV radiation of a cisplatin-resistant human cell line: overexpression of cellular factors that recognize UV-modified DNA

  1991cited by this paper
• The effect of cisplatin and carboplatin on c-myc promoter in erythroleukemic cells.

  1991cited by this paper
• Differential properties of cisplatin and tetraplatin with respect to cytotoxicity and perturbation of cellular glutathione levels

  1991cited by this paper
• Characteristics of five human tumor cell lines and sublines resistant to cis‐diamminedichloroplatinum(II)

  1991cited by this paper
• Coordinate change of c-myc, transferrin receptor and H3 gene expression precedes induction of haemoglobin-producing cells of the leukaemia K562 cell line treated with cis-diamminedichloroplatinum (II).

  1991cited by this paper
• Inhibition of adenylate cyclase by tetraplatin

  1991cited by this paper
• Cis-platin responsive sequences in the human c-myc promoter.

  1991cited by this paper
• Modulation of cis‐diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3‐isobutyl‐1‐methylxanthine in sensitive and resistant human ovarian carcinoma cells

  1991cited by this paper
• Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin.

  1990cited by this paper
• Detection of Proteins that Recognize Platinum‐modified DNA Using Gel Mobility Shift Assay

  1990cited by this paper
• How cells recognize damaged DNA: clues from xeroderma pigmentosum and yeast.

  1990cited by this paper
• Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality.

  1990cited by this paper
• Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.

  1990cited by this paper
• Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat.

  1990cited by this paper
• Binding of cis(1,2-diaminocyclohexane)platinum(II) and its derivatives to duplex DNA.

  1990cited by this paper
• Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance.

  1990cited by this paper
• Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.

  1990cited by this paper
• Role of carrier ligand in platinum resistance in L1210 cells.

  1990cited by this paper
• Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA.

  1990cited by this paper
• Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems.

  1990cited by this paper
• Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells.

  1990cited by this paper
• Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication.

  1990cited by this paper
• Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).

  1990cited by this paper
• In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma.

  1990cited by this paper
• Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.

  1989cited by this paper
• Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents

  1989cited by this paper
• Binding kinetics of tetrachloro-1,2-diaminocyclohexaneplatinum (IV) (tetraplatin) and cis-diamminedichloroplatinum (II) at 37 degrees C with human plasma proteins and with bovine serum albumin. Does aquation precede protein binding?

  1989cited by this paper
• DNA repair in cells sensitive and resistant to cis-diamminedichloroplatinum(II): host cell reactivation of damaged plasmid DNA.

  1989cited by this paper
• Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.

  1989cited by this paper
• Platinum incorporation and differential effects of cis- and trans-diamminedichloroplatinum(II) on the growth of mouse leukemia P388/D1.

  1989cited by this paper
• Conversion of monofunctional DNA adducts of cis-diamminedichloroplatinum (II) to bifunctional lesions. Effect on the in vitro replication of single-stranded DNA by Escherichia coli DNA polymerase I and eukaryotic DNA polymerases alpha.

  1989cited by this paper
• Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

  1989cited by this paper
• A comparison of the effects of tetraplatin and cisplatin on renal function and gentamicin pharmacology in rats.

  1989cited by this paper
• Pathways of human cell post-replication repair.

  1989cited by this paper
• Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes.

  1989cited by this paper
• Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

  1989cited by this paper
• Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.

  1989cited by this paper
• Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells.

  1988cited by this paper
• Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA.

  1988cited by this paper

• Elucidating CT-DNA refolding and antitumor efficacy of novel phendione-Pd(II) complexes: A comprehensive computational and experimental study.

  2025cites this paper
• The outcast of medicine: metals in medicine--from traditional mineral medicine to metallodrugs

  2025cites this paper
• The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells

  2024cites this paper
• The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in colon cancer cells

  2023cites this paper
• Synthesis, characterization and theoretical calculations of (1,2-diaminocyclohexane)(1,3-diaminopropane)gold(III) chloride complexes: in vitro cytotoxic evaluations against human cancer cell lines

  2015cites this paper
• Synthesis, spectroscopic characterization, electrochemical behavior and computational analysis of mixed diamine ligand gold(III) complexes: antiproliferative and in vitro cytotoxic evaluations against human cancer cell lines

  2014cites this paper
• CYTOTOXIC PROPERTIES OF NOVEL PLATINUM COMPOUNDS, BBR3610-DACH AND TRANS-4-NBD IN TUMOR CELLS: CELLULAR EFFECTS OF 1, 2-DACH AND NBD LIGANDS

  2013cites this paper
• Clinical Pharmacokinetics and Administration of Established Platinum Drugs

  2012cites this paper
• Synthesis, characterization and in vitro antitumour activity of a series of novel platinum(II) complexes bearing Schiff base ligands.

  2012cites this paper
• The rational design of anticancer platinum complexes: the importance of the structure-activity relationship.

  2009cites this paper
• Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.

  2008cites this paper
• Synthesis, characterization and antiproliferative studies of the enantiomers of cis-[(1,2-camphordiamine)dichloro]platinum(II) complexes.

  2008cites this paper
• Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity.

  2007cites this paper
• Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.

  2005cites this paper
• Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells

  2005cites this paper
• Synthesis and structure of new trichloroplatinum π-complexes: Reactivity of nitrogen lone-pair versus C–C double bond π-electrons in ligands, effect of steric hindrance

  2005cites this paper
• DNA interaction of dioxycyclobutenedione-(1,2-cyclohexanediamine) platinum(II) complex with potential anticancer activity.

  2005cites this paper
• Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line.

  2004cites this paper
• Mechanism of two-electron oxidation of deoxyguanosine 5'-monophosphate by a platinum(IV) complex.

  2004cites this paper
• Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines

  2004cites this paper
• Platinum(II) catalysis and radical intervention in reductions of platinum(IV) antitumor drugs by ascorbic acid.

  2003cites this paper
• Synthesis and antitumor activity of novel thermosensitive platinum(II)-cyclotriphosphazene conjugates.

  2003cites this paper
• Tamoxifen Derivatives for Delivery of the Antitumoral (DACH)Pt Group: Selective Synthesis by McMurry Coupling, and Biochemical Behaviour

  2003cites this paper
• Studies of the binding of a series of platinum(IV) complexes to plasma proteins.

  2002cites this paper
• Cellular and molecular aspects of drugs of the future: oxaliplatin

  2002cites this paper
• Preparation and cell growth inhibitory activity of [PtR(2)L(2)] (R=polyfluorophenyl, L(2)=diene, cyclohexane-1,2-diamine (chxn) or cis-(dimethyl sulfoxide)(2)) and the X-ray crystal structure of [Pt(C(6)F(5))(2)(cis-chxn)].

  2002cites this paper
• Drugs of the Future: Review Cellular and molecular aspects of drugs of the future: oxaliplatin

  2002cites this paper
• Meccanismo D'Azione E Farmacologia Di Nuovi Composti Organometallici Attivi Nel Trattamento Del Carcinoma Del Colon-Retto

  2000cites this paper
• Oxaliplatin-induced damage of cellular DNA.

  2000influential citation
• [Mechanism of action and pharmacology of new organometallic compounds active in the treatment of colorectal neoplasms].

  2000cites this paper
• Current status of platinum-based antitumor drugs.

  1999cites this paper
• Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.

  1999cites this paper
• Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line.

  1999cites this paper
• Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells

  1999cites this paper
• Effect of thiols exported by cancer cells on the stability and growth-inhibitory activity of Pt(IV) complexes

  1999cites this paper
• Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

  1998influential citation
• Activity of oxaliplatin against human tumor colony-forming units.

  1998cites this paper
• Binding of platinum-diaminonitroxyl complexes to animal DNA.

  1998cites this paper
• Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers

  1997cites this paper
• In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.

  1996cites this paper
• In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells

  1996cites this paper